These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 9572893)
1. Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias. Muccio DD; Brouillette WJ; Breitman TR; Taimi M; Emanuel PD; Zhang X; Chen G; Sani BP; Venepally P; Reddy L; Alam M; Simpson-Herren L; Hill DL J Med Chem; 1998 May; 41(10):1679-87. PubMed ID: 9572893 [TBL] [Abstract][Full Text] [Related]
2. Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity. Muccio DD; Brouillette WJ; Alam M; Vaezi MF; Sani BP; Venepally P; Reddy L; Li E; Norris AW; Simpson-Herren L; Hill DL J Med Chem; 1996 Sep; 39(19):3625-35. PubMed ID: 8809153 [TBL] [Abstract][Full Text] [Related]
3. Conformationally defined retinoic acid analogues. 5. Large-scale synthesis and mammary cancer chemopreventive activity for (2E,4E,6Z,8E)-8-(3',4'-dihydro-1'(2'H)-naphthalen-1'-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid (9cUAB30). Atigadda VR; Vines KK; Grubbs CJ; Hill DL; Beenken SL; Bland KI; Brouillette WJ; Muccio DD J Med Chem; 2003 Aug; 46(17):3766-9. PubMed ID: 12904083 [TBL] [Abstract][Full Text] [Related]
4. Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity. Alam M; Zhestkov V; Sani BP; Venepally P; Levin AA; Kazmer S; Li E; Norris AW; Zhang XK; Lee MO J Med Chem; 1995 Jun; 38(13):2302-10. PubMed ID: 7608895 [TBL] [Abstract][Full Text] [Related]
5. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites. Idres N; Benoît G; Flexor MA; Lanotte M; Chabot GG Cancer Res; 2001 Jan; 61(2):700-5. PubMed ID: 11212271 [TBL] [Abstract][Full Text] [Related]
6. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843 [TBL] [Abstract][Full Text] [Related]
7. Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells. Duprez E; Lillehaug JR; Gaub MP; Lanotte M Oncogene; 1996 Jun; 12(11):2443-50. PubMed ID: 8649786 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of papilloma formation by analogues of 7,8-dihydroretinoic acid. Shealy YF; Riordan JM; Frye JL; Simpson-Herren L; Sani BP; Hill DL J Med Chem; 2003 May; 46(10):1931-9. PubMed ID: 12723955 [TBL] [Abstract][Full Text] [Related]
9. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha. Duprez E; Lillehaug JR; Naoe T; Lanotte M Oncogene; 1996 Jun; 12(11):2451-9. PubMed ID: 8649787 [TBL] [Abstract][Full Text] [Related]
10. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. Park DJ; Chumakov AM; Vuong PT; Chih DY; Gombart AF; Miller WH; Koeffler HP J Clin Invest; 1999 May; 103(10):1399-408. PubMed ID: 10330422 [TBL] [Abstract][Full Text] [Related]
11. Design and stereoselective synthesis of retinoids with ferrocene or N-butylcarbazole pharmacophores that induce post-differentiation apoptosis in acute promyelocytic leukemia cells. Ivanova D; Gronemeyer H; de Lera AR ChemMedChem; 2011 Aug; 6(8):1518-29. PubMed ID: 21506276 [TBL] [Abstract][Full Text] [Related]